Cervical cancer is the third most common cancer in women in the world, responsible for close to 300,000 deaths annually. The cervical cancer burden is particularly severe in sub-Saharan Africa due to the absence of population-wide screening programs and a high prevalence of HIV infection. Cervical cancer is caused by infection and persistence of oncogenic alpha-clade human papillomaviruses (HPV). Oncogenic HPV types 16, 18, 31, 33, 35, 45, 52, and 58 account for approximately 92% of cervical cancer worldwide;HPV16 and HPV18 account for the largest proportion in Africa (48% and 23%, respectively) as in the rest of the world. Research over the past two decades shows that for a given HPV type, intratypic sequence variations of the HPV genome (defined as lineage and sublineages) resulting from long-term viral evolution influence the pathogenic effects of this virus family in model systems, including effects on expression of HPV oncogenes, interaction of oncogenes with cellular factors, and antigenicity. And, most studies find that the certain HPV16 lineages are associated with higher risks of persistence, pre-cancer, and cancer. Several studies hint that a patient's HIV status might influence which HPV lineage causes her cervical cancer, and that HPV sequence may influence survival. Whether HPV lineages and/or sublineages influence the burden of cervical cancer in sub-Saharan Africa is unknown. Only three studies totaling <90 cases have sequenced HPV genomes (all HPV16) in cervical cancer specimens from this region, but have not examined whether the distribution of variants is influenced by HIV status or is associated with survival. In a population of 300 first, primary, invasive cervical carcinomas diagnosed in Ugandan women, we will: 1) determine HPV types using reverse line-blot arrays, and lineages and sublineages by PCR-based direct sequencing of the LCR/E6/E7 region followed by phylogenetic analyses;2) assess associations between HPV variation and tumor and patient characteristics such as histology, stage, and HIV status;and 3) determine the association between HPV types, lineages, and sublineages and cervical cancer survival. This study will provide unique information about variation in the HPV genome and its contribution to the cervical cancer epidemic in Uganda.

Public Health Relevance

Invasive cervical cancer is the third-most common cancer in women in the world, and occurs at epidemic proportions in sub-Saharan Africa. Human papillomavirus (HPV) causes cervical cancer, and this project will determine whether variation in the HPV DNA sequence plays a role in this public health problem.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (M2))
Program Officer
Dominguez, Geraldina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Beima-Sofie, Kristin; Wamalwa, Dalton; Maleche-Obimbo, Elizabeth et al. (2018) Toll-like receptor 9 polymorphism is associated with increased Epstein-Barr virus and Cytomegalovirus acquisition in HIV-exposed infants. AIDS 32:267-270
Coghill, Anna E; Schenk, Jeannette M; Mahkoul, Zeina et al. (2018) Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda. AIDS 32:505-512
Menon, Manoj P; Coghill, Anna; Mutyaba, Innocent O et al. (2018) Association Between HIV Infection and Cancer Stage at Presentation at the Uganda Cancer Institute. J Glob Oncol :1-9
Bender Ignacio, Rachel; Ghadrshenas, Matine; Low, Daniel et al. (2018) HIV Status and Associated Clinical Characteristics Among Adult Patients With Cancer at the Uganda Cancer Institute. J Glob Oncol :1-10
Phipps, Warren; Kansiime, Rachel; Stevenson, Philip et al. (2018) Peer Mentoring at the Uganda Cancer Institute: A Novel Model for Career Development of Clinician-Scientists in Resource-Limited Settings. J Glob Oncol :1-11
Low, Daniel; Merkel, Emily C; Menon, Manoj et al. (2017) Chemotherapy Use at the End of Life in Uganda. J Glob Oncol 3:711-719
Coghill, Anna E; Schenk, Jeanette M; Mahkoul, Zeina et al. (2017) Omega-3 decreases interleukin-6 levels in HIV and HHV-8 co-infected patients: results from a randomized supplementation trial in Uganda. AIDS :
Okuku, Fred; Krantz, Elizabeth M; Kafeero, James et al. (2017) Evaluation of a Predictive Staging Model for HIV-Associated Kaposi Sarcoma in Uganda. J Acquir Immune Defic Syndr 74:548-554
Casper, Corey; Fitzmaurice, Christina (2016) Infection-related cancers: prioritising an important and eliminable contributor to the global cancer burden. Lancet Glob Health 4:e580-1